Published July 23, 2023
| Version v1
Poster
Open
Microenvironment of metastatic site reveals key predictors of PD-1 blockade response in renal cell carcinoma
Creators
- Jeanneret Florian1
- Bazelle Pauline1
- Schoch Sarah2
- Pillet Catherine1
- Um In Hwa3
- Bouzit Assilah4
- Evrand Bertrand5
- Seffar Evan6
- Chalmel Frédéric5
- Alfaro Javier7
- Pesquita Catia8
- Zanzotto Fabio Massimo9
- Stares Mark10
- Symeonides Stefan10
- Laird Alexander10
- Long Jean-Alexandre4
- Descotes Jean-Luc4
- Pflieger Delphine11
- Harrison David3
- Filhol Odile12
- Axelson Håkan2
- Battail Christophe1
- 1. CEA
- 2. Lund University
- 3. University of St Andrews
- 4. Centre hospitalier universitaire Grenoble Alpes
- 5. Univ Rennes
- 6. Memorial Sloan Kettering Cancer Center
- 7. University of Gdansk
- 8. Universidade de Lisboa
- 9. University of Rome Tor Vergata
- 10. Edinburgh Cancer Centre
- 11. CNRS
- 12. INSERM
Description
Immune checkpoint blockade (ICB) therapies are now an important tool in the arsenal for the treatment of advanced cancer extending progression-free survival and overall survival. However, only a subset of cancer patients responds to ICB therapies causing an urgent need for novel approaches to better select patients who may benefit from immunotherapy. Here, we used metastatic ccRCC samples obtained before ICB treatment and performed cell deconvolution analysis to investigate novel biomarkers of ICB treatment response.
Files
Jeanneret_ECCB-ISMB2023.pdf
Files
(259.7 kB)
Name | Size | Download all |
---|---|---|
md5:4a427cfffbb43269effeb81d41cb6438
|
259.7 kB | Preview Download |